Cadrenal Therapeutics (CVKD) Interest Expenses (2022 - 2026)
Cadrenal Therapeutics (CVKD) posted Interest Expenses of $16406.0 for Q1 2026, down 94.51% sequentially from $299096.0 in Q4 2025, and down 98.15% YoY from $885444.0 in Q1 2025.
Cadrenal Therapeutics (CVKD) Interest Expenses (2022 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Interest Expenses for 5 years, with the latest figure at $16406.0 in Q1 2026.
- Quarterly Interest Expenses fell 98.15% year-over-year to $16406.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16406.0 (down 98.15% YoY) and the FY2025 annual result came in at $7.9 million, up 67.2% from the prior year.
- Interest Expenses fell to $16406.0 in Q1 2026 per CVKD's latest filing, from $299096.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $4.7 million in Q4 2024 and troughed at $456.0 in Q1 2024.
- A 5-year average of $584848.4 and a median of $244965.0 in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses tumbled 99.94% in 2024, then soared 194076.32% in 2025.
- Over 5 years, Interest Expenses stood at $18104.0 in 2022, then surged by 3988.26% to $740139.0 in 2023, then surged by 540.96% to $4.7 million in 2024, then tumbled by 93.7% to $299096.0 in 2025, then slumped by 94.51% to $16406.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $16406.0, $299096.0, and $299096.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Cadrenal Therapeutics | 4.59 Mn | 2.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9,375.00 |
| Jun 30, 2026 | 9,375.00 |
| Mar 31, 2026 | 16,406.00 |
| Mar 31, 2026 | 16,406.00 |
| Dec 31, 2025 | 299,096.00 |
| Dec 31, 2025 | 299,096.00 |
| Sep 30, 2025 | 299,096.00 |
| Sep 30, 2025 | 299,096.00 |
| Jun 30, 2025 | 190,834.00 |
| Jun 30, 2025 | 190,834.00 |
| Mar 31, 2025 | 885,444.00 |
| Mar 31, 2025 | 885,444.00 |
| Dec 31, 2024 | 4.74 Mn |
| Dec 31, 2024 | 4.74 Mn |
| Sep 30, 2024 | 327,000.00 |
| Sep 30, 2024 | 327,000.00 |
| Jun 30, 2024 | 8,928.00 |
| Jun 30, 2024 | 8,928.00 |
| Mar 31, 2024 | 456.00 |
| Mar 31, 2024 | 456.00 |